D. E. Shaw & Co., Inc.
- SEC CIK
- 0001009207
- Latest filing
- Aug 14, 2026
YMAB holding history
Y-mAbs Therapeutics, Inc. in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
YMAB overviewAll 13F holders of YMABFull Q2 2026 holdings
- Shares (Q3 2025)
- 0
- Sold out in Q3 2025
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 16
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q3 2025 | 0 | $0 | 0.0% | −516,857−100.0% | Sold out | Holders |
| Q2 2025 | 516,857 | $2.33M | <0.1% | −32,809−6.0% | Reduced | Holders |
| Q1 2025 | 549,666 | $2.44M | <0.1% | −65,465−10.6% | Reduced | Holders |
| Q4 2024 | 615,131 | $4.82M | <0.1% | −172,405−21.9% | Reduced | Holders |
| Q3 2024 | 787,536 | $10.4M | <0.1% | −138,921−15.0% | Reduced | Holders |
| Q2 2024 | 926,457 | $11.2M | <0.1% | −141,702−13.3% | Reduced | Holders |
| Q1 2024 | 1,068,159 | $17.4M | <0.1% | −255,621−19.3% | Reduced | Holders |
| Q4 2023 | 1,323,780 | $9.03M | <0.1% | −25,430−1.9% | Reduced | Holders |
| Q3 2023 | 1,349,210 | $7.35M | <0.1% | +73,813+5.8% | Added | Holders |
| Q2 2023 | 1,275,397 | $8.66M | <0.1% | +484,441+61.2% | Added | Holders |
| Q1 2023 | 790,956 | $3.96M | <0.1% | +322,292+68.8% | Added | Holders |
| Q4 2022 | 468,664 | $2.29M | <0.1% | +353,174+305.8% | Added | Holders |
| Q3 2022 | 115,490 | $1.67M | <0.1% | +74,103+179.0% | Added | Holders |
| Q2 2022 | 41,387 | $626.0K | <0.1% | −97,270−70.2% | Reduced | Holders |
| Q1 2022 | 138,657 | $1.65M | <0.1% | +138,657 | New | Holders |
| Q3 2021 | 0 | $0 | 0.0% | −39,083−100.0% | Sold out | Holders |
| Q2 2021 | 39,083 | $1.32M | <0.1% | −41,382−51.4% | Reduced | Holders |
| Q1 2021 | 80,465 | $2.43M | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.